An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
Price : $35 *
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 02 Jun 2015 Enrolment was completed at the end of June 2014, according to an abstract presented at ASCO 2015.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2015 Status changed from recruiting to completed, according to an abstract presented at ASCO 2015.